Patents by Inventor Michael Carl Irizarry

Michael Carl Irizarry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy
    Patent number: 11839654
    Abstract: The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: December 12, 2023
    Assignee: Eli Lilly and Company
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry, Hugh Nuthall
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20220235122
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (A?), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 28, 2022
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 11312763
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • COMBINATION THERAPY
    Publication number: 20210301003
    Abstract: A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.
    Type: Application
    Filed: March 24, 2021
    Publication date: September 30, 2021
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry
  • Combination Therapy
    Publication number: 20210121565
    Abstract: The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.
    Type: Application
    Filed: January 5, 2021
    Publication date: April 29, 2021
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry, Hugh Nuthall
  • Combination therapy
    Patent number: 10988529
    Abstract: A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 27, 2021
    Assignee: Eli Lilly and Company
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry
  • ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
    Publication number: 20190382471
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Application
    Filed: June 23, 2017
    Publication date: December 19, 2019
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • COMBINATION THERAPY
    Publication number: 20190161539
    Abstract: A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody.
    Type: Application
    Filed: August 3, 2017
    Publication date: May 30, 2019
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry